
ZoeNCure Licenses Novel Antibody Tech for Dual-Payload ADCs in Liver Cancer
The story in brief
ZoeNCure Therapeutics Pvt. Ltd., based in New Delhi, India, has secured a license for a novel antibody platform from San Diego-based Styx Biotechnologies to develop next-generation ADCs for liver cancer. The collaboration targets hepatocellular carcinoma, a critical unmet medical need in South Asia, with therapies designed to deliver dual therapeutic mechanisms.